Julie R. Gralow, MD

Julie R. Gralow, MD, discusses the integration of precision medicine into oncology.

Julie R. Gralow, MD, clinical director, Breast Medical Oncology, Seattle Cancer Care Alliance, professor, medical oncology, University of Washington School of Medicine, discusses the global impact of biosimilars in HER2-positive breast cancer.

Julie R. Gralow, MD, discusses the science of biosimilars and their implementation in breast cancer.

Julie R. Gralow, MD, discusses the use of bisphosphonates in early-stage breast cancer.

Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, clinical research division, member, Fred Hutchinson Cancer Care Center, professor, Medical Oncology Division, University of Washington School of Medicine, discusses toxicities observed in the SWOG S0307 trial, which examined bisphosphonates as adjuvant therapy in primary breast cancer.

Julie R. Gralow, MD, from the Seattle Cancer Care Alliance, discusses the SWOG S0500 trial, which evaluated different therapies for patients with metastatic breast cancer who had elevated circulating tumor cell levels.

Julie R. Gralow, MD, from Seattle Cancer Care Alliance, discusses the side effects associated with the administration of zoledronic acid.

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, Discusses the Antibody Drug Conjugate T-DM1 for Breast Cancer.

Dr. Julie Gralow from the Seattle Cancer Care Alliance Discusses T-DM1-Induced Thrombocytopenia

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Treating Breast Cancer Bone Metastases

Dr. Julie Gralow, from the Seattle Cancer Care Alliance, on Adjuvant Bisphosphonates for Breast Cancer